Understanding how antiviral treatments for HIV lose effectiveness during treatment breaks
Official title: Characterizing Antiviral Washout and Viral Rebound during Analytic Treatment Interruption Studies
Funded at University of California, San Francisco · NIH-11143903 · Data updated 2026-11-12
This study is looking at how stopping antiviral treatments for HIV affects their effectiveness, especially focusing on how well certain therapies work when treatment is paused, so we can better understand how to improve future HIV treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 24, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $205,000 |
| NIH project number | 5R21AI184166-02 |
| Project ID | NIH-11143903 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are undergoing or have undergone treatment interruption.
✕Less likely to help
Patients who are not living with HIV or those who are not eligible for treatment interruption may not benefit from this research.
What this research studies
This research investigates how the effectiveness of antiviral treatments, specifically antiretroviral therapy (ART) and broadly neutralizing antibodies (bnAbs), diminishes during periods when treatment is paused in individuals with HIV. By analyzing existing data and samples from previous studies, the research aims to measure the levels of ART in the body and how these levels relate to the resurgence of the virus. Additionally, it will explore the role of bnAbs in controlling the virus compared to immune responses. The findings will help inform future clinical trials aimed at curing HIV and improving treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for curing HIV and enhancing treatment protocols.
How similar studies have gone: Previous research has shown promise in understanding viral dynamics during treatment interruptions, but this specific approach using bnAbs is relatively novel.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Deitchman, Amelia N — University of California, San Francisco
- Study coordinator: Deitchman, Amelia N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.